Current use and potential role of procalcitonin in the diagnostic work up and follow up of febrile neutropenia in hematological patients

References

• Averbuch D, Coedonnier C, Livermore DM, et al. Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011). Hematol. 2013;98:1836–1847.
   Google Scholar
• Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52:427–431.
   PubMed Web of Science ®Google Scholar
• Penack O, Becker C, Buchheidt D, et al. Management of sepsis in neutropenic patients: 2014 updated guidelines from the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO). Ann Hematol. 2014;93:1083–1095.
   PubMed Web of Science ®Google Scholar
• Hambach L, Eder M, Dammann E, et al. Diagnostic value of procalcitonin serum levels in comparison with C-reactive protein in allogeneic stem cell transplantation. Haematologica. 2002;87:643–651.
   PubMed Web of Science ®Google Scholar
• Schüttrumpf S, Binder L, Hagemann T, et al. Procalcitonin: a useful discriminator between febrile conditions of different origin in hemato-oncological patients? Ann Hematol. 2003;82:98–103.
   PubMed Web of Science ®Google Scholar
• Giamarellou H, Giamarellos-Bourboulis EJ, Repoussis P, et al. Potential use of procalcitonin as a diagnostic criterion in febrile neutropenia: experience from a multicentre study. Clin Microbiol Infect. 2004;10:628–633.
   PubMed Web of Science ®Google Scholar
• Prat C, Sancho JM, Dominguez J, et al. Evaluation of procalcitonin, neopterin, C-reactive protein, IL-6 and IL-8 as a diagnostic marker of infection in patients with febrile neutropenia. Leuk Lymphoma. 2008;49:1752–1761.
   PubMed Web of Science ®Google Scholar
• Aimoto M, Koh H, Katayama T, et al. Diagnostic performance of serum high-sensitivity procalcitonin and serum C-reactive protein tests for detecting bacterial infection in febrile neutropenia. Infection. 2014;42:971–979.
   PubMed Web of Science ®Google Scholar
• Simon L, Gauvin F, Amre DK, et al. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis. 2004;39:206–217.
   PubMed Web of Science ®Google Scholar
• Scirè CA, Cavagna L, Perotti C, et al. Diagnostic value of procalcitonin measurement in febrile patients with systemic autoimmune diseases. Clin Exp Rheumatol. 2006;24:123–128.
   PubMed Web of Science ®Google Scholar
• Dalkey N, Olaf H. An experimental application of the Delphi method to the use of experts. Manage Sci. 1963;9:458–467.
   Web of Science ®Google Scholar
• Rowe G, Wright G. The Delphi technique as a forecasting tool: issues and analysis. Int J Forecast. 1999;15(Issue):4.
   Google Scholar
• Hangai S, Nannya Y, Kurokawa M. Role of procalcitonin and C-reactive protein for discrimination between tumor fever and infection in patients with hematological diseases. Leuk Lymphoma. 2015;56:910–914.
   PubMed Web of Science ®Google Scholar
• Koya J, Nannya Y, Ichikawa M, et al. The clinical role of procalcitonin in hematopoietic SCT. Bone Marrow Transplant. 2012;47:1326–1331.
   PubMed Web of Science ®Google Scholar
• Sato M, Nakasone H, Terasako-Saito K, et al. Prediction of infectious complications by the combination of plasma procalcitonin level and localized infection before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2014;49:553–560.
   PubMed Web of Science ®Google Scholar
• Richter ME, Neugebauer S, Engelmann F, et al. Biomarker candidates for the detection of an infectious etiology of febrile neutropenia. Infection. 2016;44:175–186.
   PubMed Web of Science ®Google Scholar
• Blijlevens NM, Donnelly JP, Meis JF, et al. Procalcitonin does not discriminate infection from inflammation after allogeneic bone marrow transplantation. Clin Diagn Lab Immunol. 2000;7:889–892.
   PubMedGoogle Scholar
• Duarte RF, Sánchez-Ortega I, Cuesta I, et al. Serum galactomannan–based early detection of invasive aspergillosis in hematology patients receiving effective antimold prophylaxis. Clin Infect Dis. 2014;59:1696–1702.
   PubMed Web of Science ®Google Scholar
• Bergeron A, Porcher RL, Sulahian A, et al. The strategy for the diagnosis of invasive pulmonary aspergillosis should depend on both the underlying condition and the leukocyte count of patients with hematologic malignancies. Blood. 2012;119:1831–1837.
   PubMed Web of Science ®Google Scholar
• Roques M, Chretien ML, Favennec C, et al. Evolution of procalcitonin, C-reactive protein and fibrinogen levels in neutropenic leukaemia patients with invasive pulmonary aspergillosis or mucormycosis. Mycoses. 2016;59:383–390.
   PubMed Web of Science ®Google Scholar
• Klastersky J, Paesmans M, Rubenstein EB, et al. The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18:3038–3051.
   PubMed Web of Science ®Google Scholar
• De Souza Viana L, Serufo JC, Da Costa Rocha MO, et al. Performance of a modified MASCC index score for identifying low-risk febrile neutropenic cancer patients. Support Care Cancer. 2008;16:841–846.
   PubMed Web of Science ®Google Scholar
• Apostolopoulou E, Raftopoulos V, Terzis K, et al. Infection probability score, APACHE II and KARNOFSKY scoring systems as predictors of bloodstream infection onset in hematology oncology patients. BMC Infect Dis. 2010;10:135.
   PubMed Web of Science ®Google Scholar
• Ahn S, Lee YS, Lim KS, et al. Adding procalcitonin to the MASCC risk-index score could improve risk stratification of patients with febrile neutropenia. Support Care Cancer. 2013;21:2303–2308.
   PubMed Web of Science ®Google Scholar
• Ahn S, Lee YS, Lee JL, et al. A new prognostic model for chemotherapy-induced febrile neutropenia. Int J Clin Oncol. 2016;21:46–52.
   PubMed Web of Science ®Google Scholar
• Bernard L, Ferriere F, Casassus P, et al. Procalcitonin as an early marker of bacterial infection in severely neutropenic febrile adults. Clin Infect Dis. 1998;27:914–915.
   PubMed Web of Science ®Google Scholar
• Wu CW, Juan JY, Chen CK, et al. Does procalcitonin, C-reactive protein, or interleukin-6 test have a role in the diagnosis of severe infection in patients with febrile neutropenia? A systematic review and meta-analysis. Support Care Cancer. 2015;23:2863–2872.
   PubMed Web of Science ®Google Scholar
• Engel A1, Steinbach G, Kern P, et al. Diagnostic value of procalcitonin serum levels in neutropenic patients with fever: comparison with interleukin-8. Scand J Infect Dis. 1999;31:185–189.
   PubMed Web of Science ®Google Scholar
• Petrikkos GL, Christofilopoulou SA, Tentolouris NK, et al. Value of measuring serum procalcitonin, C-reactive protein, and mannan antigens to distinguish fungal from bacterial infections. Eur J Clin Microbiol Infect Dis. 2005;24:272–275.
   PubMed Web of Science ®Google Scholar
• Svaldi M1, Hirber J, Lanthaler AI, et al. Procalcitonin-reduced sensitivity and specificity in heavily leucopenic and immunosuppressed patients. Br J Haematol. 2001;115:53–57.
   PubMed Web of Science ®Google Scholar
• BalcI C, Sungurtekin H, Gürses E, et al. Usefulness of procalcitonin for diagnosis of sepsis in the intensive care unit. Crit Care. 2003;7:85–90.
   PubMed Web of Science ®Google Scholar
• Lima SS, Nobre V, De Castro Romanelli RM, et al. Procalcitonin-guided protocol is not useful to manage antibiotic therapy in febrile neutropenia: a randomized controlled trial. Ann Hematol. 2016;95:1169–1176.
   PubMed Web of Science ®Google Scholar
• Beaune G, Bienvenu F, Pondarré C, et al. Serum procalcitonin rise is only slight in two cases of disseminated aspergillosis. Infection. 1998;26:168–169.
   PubMed Web of Science ®Google Scholar
• Huber W, Schweigart U, Bottermann P, et al. Failure of PCT to indicate severe fungal infection in two immunodeficient patients. Infection. 1997;25:377–378.
   PubMed Web of Science ®Google Scholar
• Christofilopoulou S, Charvalos E, Petrikkos G. Could procalcitonin be a predictive biological marker in systemic fungal infections? Study of 14 cases. Eur J Intern Med. 2002;13:493–495.
   PubMedGoogle Scholar
• Ortega M, Rovira M, Filella X, et al. Prospective evaluation of procalcitonin in adults with febrile neutropenia after haematopoietic stem cell transplantation. Br J Haematol. 2004;126:372–376.
   PubMed Web of Science ®Google Scholar
• Fernández Lopez A, Luaces Cubells C, García García JJ, et al. Procalcitonin in pediatric emergency departments for the early diagnosis of invasive bacterial infections in febrile infants: results of a multicenter study and utility of a rapid qualitative test for this marker. Pediatr Infect Dis J. 2003;22:895–903.
   PubMed Web of Science ®Google Scholar
• Andreola B, Bressan S, Callegaro S, et al. Procalcitonin and C-reactive protein as diagnostic markers of severe bacterial infections in febrile infants and children in the emergency department. Pediatr Infect Dis J. 2007;26:672–677.
   PubMed Web of Science ®Google Scholar
• Mikulska M, Viscoli C, Orasch C, et al. Fourth European Conference on Infections in Leukemia Group (ECIL-4), a joint venture of EBMT, EORTC, ICHS, ELN and ESGICH/ESCMID. Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients. J Infect. 2014;68:321–331.
   PubMed Web of Science ®Google Scholar
• Gustinetti G, Mikulska M. Bloodstream infections in neutropenic cancer patients: A practical update. Virulence. 2016;7:280–297.
   PubMed Web of Science ®Google Scholar
• Hatzistilianou M, Rekliti A, Athanassiadou F, et al. Procalcitonin as an early marker of bacterial infection in neutropenic febrile children with acute lymphoblastic leukemia. Inflamm Res. 2010;59:339–347.
   PubMed Web of Science ®Google Scholar
• Lin SG, Hou TY, Huang DH, et al. Role of procalcitonin in the diagnosis of severe infection in pediatric patients with fever and neutropenia – a systemic review and meta-analysis. Pediatr Infect Dis J. 2012;31:82–88.
   PubMed Web of Science ®Google Scholar
• Marková M, Brodská H, Malíčková K, et al. Substantially elevated C-reactive protein (CRP), together with low levels of procalcitonin (PCT), contributes to diagnosis of fungal infection in immunocompromised patients. Support Care Cancer. 2013;21:2733–2742.
   PubMed Web of Science ®Google Scholar
• Brodska H, Drabek T, Malickova K, et al. Marked increase of procalcitonin after the administration of anti-thymocyte globulin in patients before hematopoietic stem cell transplantation does not indicate sepsis: a prospective study. Crit Care. 2009;13:R37.
   PubMed Web of Science ®Google Scholar
• Chaftari AM, Hachem R, Reitzel R, et al. Role of procalcitonin and interleukin-6 in predicting cancer, and its progression independent of infection. Plos One. 2015;10.
   Web of Science ®Google Scholar
• Squadrone V, Massaia M, Bruno B, et al. Early CPAP prevents evolution of acute lung injury in patients with hematologic malignancy. Intensive Care Med. 2010;36:1666–1674.
   PubMed Web of Science ®Google Scholar
• Singer M, Deutschaman CS, Seymour CW. The third international consensus definitions for sepsis and septic shock (sepsis-3). Jama. 2016;315:801–810.
   PubMed Web of Science ®Google Scholar
• Kaukonen KM, Bailey M, Bellomo R. Systemic inflammatory response syndrome criteria for severe sepsis. N Engl J Med. 2015;373:881.
   PubMed Web of Science ®Google Scholar
• Phua J, Koay ES, Lee KH. Lactate, procalcitonin, and amino-terminal pro-B-type natriuretic peptide versus cytokine measurements and clinical severity scores for prognostication in septic. Shock.Shock. 2008;29:328–333.
   PubMed Web of Science ®Google Scholar
• Samraj RS, Zingarelli B, Wong HR. Role of biomarkers in sepsis care. Shock. 2013;40:358–365.
   PubMed Web of Science ®Google Scholar
• Wacker C, Prkno A, Brunkhorst FM, et al. Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. Lancet Infect Dis. 2013;13:426–435.
   PubMed Web of Science ®Google Scholar
• Bouadma L, Luyt CE, Tubach F, et al. PRORATA trial group. Use of procalcitonin to reduce patients’ exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet. 2010;375:463–474.
   PubMed Web of Science ®Google Scholar
• Wolff M, Bouadma L. What procalcitonin brings to management of sepsis in the ICU. Crit Care. 2010;14:1007.
   PubMed Web of Science ®Google Scholar
• Taur Y, Jenq RR, Perales MA. Littmann ER. The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation. Blood. 2014;124:1174–1182.
   PubMed Web of Science ®Google Scholar
• Bele N, Darmon M, Coquet I. Diagnostic accuracy of procalcitonin in critically ill immunocompromised patients. BMC Infect Dis. 2011;11:224.
   PubMed Web of Science ®Google Scholar
• De Jong E, Van Oers JA, Beishuizen A, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis. 2016;16:819–827.
   PubMed Web of Science ®Google Scholar
• Van Der Does Y, Limper M, Schuit SC, et al. Higher diagnostic accuracy and cost-effectiveness using procalcitonin in the treatment of emergency medicine patients with fever (the HiTEMP study): a multicenter randomized study. BMC Emerg Med. 2016;16:17.
   PubMed Web of Science ®Google Scholar
• Cochon L, Ovalle A, Nicolás JM, et al. A cute care diagnostic collaboration: Bayesian modeling comparative diagnostic assessment of lactate, procalcitonin and CRP in risk stratified population by Mortality in Emergency Department (MEDS) score. Am J Emerg Med. 2017;35(4):564–568.
   PubMed Web of Science ®Google Scholar